Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
129.4 USD | +1.62% | +12.41% | +34.78% |
Financials (USD)
Sales 2024 * | 1.85B | Sales 2025 * | 2.9B | Capitalization | 12.04B |
---|---|---|---|---|---|
Net income 2024 * | 214M | Net income 2025 * | 1B | EV / Sales 2024 * | 5.86 x |
Net cash position 2024 * | 1.2B | Net cash position 2025 * | 2.59B | EV / Sales 2025 * | 3.26 x |
P/E ratio 2024 * |
55.9
x | P/E ratio 2025 * |
12.2
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.56% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | +2.53% | ||
1 week | +9.30% | ||
Current month | -1.60% | ||
1 month | -0.43% | ||
3 months | +6.14% | ||
6 months | +18.79% | ||
Current year | +32.11% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 130 | +2.03% | 505 315 |
24-04-25 | 127.4 | +2.53% | 1,694,410 |
24-04-24 | 124.2 | +6.09% | 1,500,200 |
24-04-23 | 117.1 | +0.14% | 568,912 |
24-04-22 | 117 | +1.16% | 889,164 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.11% | 12.04B | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.79% | 22.02B | |
-17.84% | 20.9B | |
-11.11% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
-26.18% | 8.08B |
- Stock Market
- Equities
- SRPT Stock